Puma Biotechnology

332 articles with Puma Biotechnology

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021

  6/4/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 2, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 30,375 shares of Puma common stock to five new non-executive employees.

• Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting

  6/4/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the Phase II SUMMIT basket trial, assessing the efficacy of neratinib in patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC)

• Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL Trial with the Neratinib Arm of the Phase III ExteNET Trial at the ASCO 2021 Annual Meeting

  6/4/2021

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with the neratinib treatment arm of the ExteNET Trial

• Puma Biotechnology Presents Data from the Phase III ExteNET Trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting

  6/4/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented results from the Phase III ExteNET trial assessing the impact of neratinib treatment duration on overall survival (OS) in patients with early stage HER2-positive breast cancer at the virtual 2021 ASCO Annual Meeting

• Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting

  5/19/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8, 2021. Puma will present three posters with audio recordings, the corresponding abstracts of which are now live on the 2021 ASCO Annual Meeting website.

• Puma Biotechnology Reports First Quarter 2021 Financial Results

  5/6/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2021

  5/4/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on May 3, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 14,500 shares of Puma common stock to three new non-executive employees.

• Puma Biotechnology to Host Conference Call to Discuss First Quarter 2021 Financial Results

  4/22/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 6, 2021, following the release of its first quarter 2021 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Apr 13, 2021

  4/13/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on April 12, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 36,500 shares of Puma common stock to six new non-executive employees.

• Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen

  3/16/2021

  - Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA ® and Puma’s NERLYNX ® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test - This is Celcuity’s second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Mar 08, 2021

  3/8/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on March 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering an aggregate of 3,500 shares of Puma common stock to one new non-executive employee.

• Puma Biotechnology to Present at the Barclays Global Healthcare Conference

  3/4/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the Barclays Global Healthcare Conference, which will be held virtually from March 9-11, 2021.

• Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright Global Life Sciences Conference, which will be held virtually on March 9-10, 2021.

• Puma Biotechnology Reports Fourth Quarter and Full Year Financial 2020 Results

  2/25/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2020.

• Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

  2/25/2021

  Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX® (neratinib) within Europe, Turkey, Middle East and Africa.

• Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results

  2/11/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 25, 2021, following release of its fourth quarter and full year 2020 financial results.

• Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Feb 09, 2021

  2/9/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that on February 4, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 11,000 shares of Puma common stock to two new non-executive employees.

• Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020

  1/29/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations who have been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI).

• Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI

  1/15/2021

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the biliary tract cancers cohort of the ongoing SUMMIT trial of neratinib at the virtual 2021 Gastrointestinal Cancers Symposium hosted by the American Society of Clinical Oncology (ASCO GI) that is currently taking place. The presentation, entitled, “Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers wit

• Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference - Jan 05, 2021

  1/5/2021

  Puma Biotechnology, Inc., a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the 39th Annual J.P. Morgan Healthcare Conference, which will be held virtually. Puma’s presentation will take place at 7:50 a.m. PST on Thursday, January 14, 2021.